Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2007

01.08.2007 | Original Paper

Community pharmacists’ views, attitudes and early experiences of over-the-counter simvastatin

verfasst von: Denise Hansford, Scott Cunningham, Dai John, Dorothy McCaig, Derek Stewart

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Aim

To describe community pharmacists’ views, attitudes and early experiences of OTC simvastatin.

Method

A cross-sectional postal questionnaire survey of the main pharmacist in 2000 randomly selected community pharmacy premises in Great Britain (approximately 15%).

Main outcome measure

The questionnaire comprised items on: attitudes to OTC simvastatin; continuing education; sales; and general views and experiences. Data were analysed using descriptive statistics and content analysis of responses to open questions.

Results

Questionnaires were returned by 1,156 community pharmacists (57.8%). Nine hundred and fifty-six respondents (82.7%) reported no sales of simvastatin in the previous fourteen days. Eighty-two (7.1%) sold one pack, 40 (3.5%) sold two packs and 18 (1.6%) sold three packs or more (60 did not answer). Almost all respondents (1,086, 93.9%) stated that they had participated in continuing education. Most (691/1,148, 60.1%) strongly agreed or agreed that they were entirely confident about selling simvastatin and that community pharmacists could make an appropriate risk assessment for the use of simvastatin (898/1,149, 78.2%). Responses to the open question identified a number of themes including: need for access to clinical information; cost as a barrier to supply; those purchasing were least likely to benefit; and the lack of an evidence base for the OTC dose.

Conclusion

Community pharmacists surveyed had undertaken an array of continuing education and felt confident to undertake cardiovascular risk assessment. However, very few sales of OTC simvastatin had been made and a variety of issues were identified, particularly relating to the evidence base, access to clinical information, cost and the product licence.
Literatur
1.
Zurück zum Zitat Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ Collaborators efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.PubMedCrossRef Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ Collaborators efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.PubMedCrossRef
2.
Zurück zum Zitat National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events, Technology Appraisal 94. NICE: London 2006. Available at http://www.nice.org.uk [Accessed May 2006]. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events, Technology Appraisal 94. NICE: London 2006. Available at http://​www.​nice.​org.​uk [Accessed May 2006].
3.
Zurück zum Zitat National Service Framework for Coronary Heart Disease. London: Department of Health; 2000. Available at www.doh.gov.uk/nsf/coronary.htm [Accessed May 2006]. National Service Framework for Coronary Heart Disease. London: Department of Health; 2000. Available at www.doh.gov.uk/nsf/coronary.htm [Accessed May 2006].
4.
Zurück zum Zitat Reclassification summary for simvastatin POM to P. Medicines and Healthcare Products Regulatory Agency at http://medicines.mhra_gov.uk [Accessed May 2006]. Reclassification summary for simvastatin POM to P. Medicines and Healthcare Products Regulatory Agency at http://​medicines.​mhra_​gov.​uk [Accessed May 2006].
5.
Zurück zum Zitat Johnson & Johnson MSD Consumer Pharmaceuticals. Zocor Heart-Pro Pharmacist Training Guide, 2004. Johnson & Johnson MSD Consumer Pharmaceuticals. Zocor Heart-Pro Pharmacist Training Guide, 2004.
6.
Zurück zum Zitat Royal Pharmaceutical Society of Great Britain. Practice guidance: OTC simvastatin 10 mg. Pharm J 2004;273:169–70. Royal Pharmaceutical Society of Great Britain. Practice guidance: OTC simvastatin 10 mg. Pharm J 2004;273:169–70.
7.
Zurück zum Zitat Editorial. Over-the-counter simvastatin given the go-ahead. Pharm J 2004;272:595. Editorial. Over-the-counter simvastatin given the go-ahead. Pharm J 2004;272:595.
8.
9.
Zurück zum Zitat Editorial. OTC Statins: a bad decision for public health. Lancet 2004;363:9422. Editorial. OTC Statins: a bad decision for public health. Lancet 2004;363:9422.
10.
Zurück zum Zitat Which? Medicines: enabling informed choices 2005 http://www.which.net/campaigns/health/medicines/0501medicines_br.pdf [Accessed May 2006]. Which? Medicines: enabling informed choices 2005 http://​www.​which.​net/​campaigns/​health/​medicines/​0501medicines_​br.​pdf [Accessed May 2006].
11.
Zurück zum Zitat Blenkinsopp J, Gathoga L, O’Connell K, Mukhtar M, Rehman I, Shan N, Tariq M. OTC simvastatin supply––what changes in practice and education do pharmacists want? Pharm J 2004;273:191–93. Blenkinsopp J, Gathoga L, O’Connell K, Mukhtar M, Rehman I, Shan N, Tariq M. OTC simvastatin supply––what changes in practice and education do pharmacists want? Pharm J 2004;273:191–93.
12.
Zurück zum Zitat Neuendorf KA. The Content Analysis Guidebook. London: Sage; 2002. ISBN 0761919783. Neuendorf KA. The Content Analysis Guidebook. London: Sage; 2002. ISBN 0761919783.
13.
Zurück zum Zitat Choudhry NK, Avorn J. Over-the counter statins. Ann Intern Med 2005;142:910–13.PubMed Choudhry NK, Avorn J. Over-the counter statins. Ann Intern Med 2005;142:910–13.PubMed
14.
Zurück zum Zitat Dyer O. FDA rejects sale of over the counter statins. Brit Med J 2005;330:614. Dyer O. FDA rejects sale of over the counter statins. Brit Med J 2005;330:614.
15.
Zurück zum Zitat McKenney JM, Brown WV, Cohen JD, Cahill E. The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea? Am J Cardiol 2004;94(suppl):16F–21F.PubMedCrossRef McKenney JM, Brown WV, Cohen JD, Cahill E. The National Lipid Association surveys of consumers, physicians, and pharmacists regarding an over-the-counter statin in the United States: is this a good idea? Am J Cardiol 2004;94(suppl):16F–21F.PubMedCrossRef
16.
Zurück zum Zitat Bissell P, Savage I, Anderson C. A qualitative study of pharmacists’ perspectives on the supply of emergency hormonal contraception via patient group directions in the UK. Contraception 2006;73:265–270.PubMedCrossRef Bissell P, Savage I, Anderson C. A qualitative study of pharmacists’ perspectives on the supply of emergency hormonal contraception via patient group directions in the UK. Contraception 2006;73:265–270.PubMedCrossRef
Metadaten
Titel
Community pharmacists’ views, attitudes and early experiences of over-the-counter simvastatin
verfasst von
Denise Hansford
Scott Cunningham
Dai John
Dorothy McCaig
Derek Stewart
Publikationsdatum
01.08.2007
Verlag
Kluwer Academic Publishers
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2007
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9084-4

Weitere Artikel der Ausgabe 4/2007

International Journal of Clinical Pharmacy 4/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.